VectivBio Holding AG (VECT) Stock News
NASDAQ:VECT - Nasdaq - CH1109007893 - Common Stock - Currency: USD
VECT Latest News, Press Relases and Analysis
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
Mentions: IRWD
VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals
BASEL, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical...
Why Shares of VectivBio Holding Are Up Today
A buyout offer by Ironwood Pharmaceuticals lifted the clinical-stage biotech's stock.
Mentions: IRWD
VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
Mentions: IRWD
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned.
Mentions: IRWD
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
Both companies are working on treatments for gastrointestinal diseases.
VECT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of VectivBio Holding AG Is Fair to Shareholders
Ironwood stock falls on deal to buy VectivBio for $1B (NASDAQ:IRWD)
Ironwood Pharmaceuticals (IRWD) fell ~15% in the pre-market Monday after the company agreed to acquire the Swiss biotech VectivBio for nearly $1B. Read more here.
Mentions: IRWD
VectivBio Publishes Invitation to the Annual General Meeting
BASEL, Switzerland, May 10, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company...
VectivBio Reports Full Year 2022 Financial Results and Provides Business Update
Continued Strong Progress and Momentum Across Multiple Programs with Key Upcoming Data Milestones Beginning Q2 2023 STARS Phase 3 Program of Apraglutide...
VectivBio files for $350M mixed shelf offering (NASDAQ:VECT)
VectivBio Holdings (VECT) has filed for a $350M mixed shelf offering.
VectivBio initiated at buy at Jefferies on promise for intestinal disease candidate
Jefferies has initiated VectivBio (VECT) with a buy saying that its GLP2 candidate apraglutide "could revolutionize short bowel syndrome-intestinal failure."